USFDA concludes audit at Jubilant Generics Roorkee site

Noida: Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) has concluded audit of the solid dosage formulations facility on February 2, 2024 at Roorkee site, India of Jubilant Generics Limited (‘Company’), a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The USFDA has issued 4 observations pursuant to the completion of audit.

The company will submit an action plan on the observations. The company currently supplies only one product to US from Roorkee facility, that contributed less than one percent of Jubilant Pharmova’s 9M’FY24 revenues.

Read also: Jubilant Generics Roorkee facility determined as official action indicated